Vera Therapeutics reported a net loss of $93.7 million, or $1.30 per share, for the third quarter ended September 30, 2026, compared to a net loss of $80.3 million in the prior-year period. The company generated $10.3 million in net product revenue from its TRUTAKNA launch, which received FDA accelerated approval on July 7 and has seen approximately 700 Patient Start Forms submitted since then. Operating expenses rose to $106 million due to a $34 million increase in selling, general and administrative costs associated with the commercial launch, partially offset by lower research and development expenses of $41.3 million. The company holds $384 million in cash and marketable securities as of quarter-end. Vera Therapeutics is a commercial-stage biotechnology company focused on developing therapies for autoimmune diseases, primarily targeting IgA nephropathy with its flagship product TRUTAKNA.
